Continuous Renal Replacement Therapy (CRRT) Market Size, Share & Industry Analysis, By Product Type (Systems and Consumables (Dialysates, Replacement Solutions, Filters, Catheters, and Others)), By Modality (Slow Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF)), and Regional Forecast, 2024-2032

The global continuous renal replacement therapy (CRRT) market size was valued at USD 1.04 billion in 2023 and is projected to grow from USD 1.12 billion in 2024 to USD 2.07 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period (2024-2032). North America dominated the global continuous renal replacement therapy market with a market share of 40.38% in 2023. Moreover, the U.S. continuous renal replacement therapy market size is projected to grow significantly, reaching an estimated value of USD 759.9 million by 2032, driven by increasing ICU admissions of patients with acute kidney injuries.

CRRT plays a vital role in the management of renal function in critically ill patients who suffer from Acute Kidney Injury. It is a slower, continuous, 24-hour dialysis therapy method that helps patients with hemodynamic instability. This therapy involves the removal of solutes from the blood through the process of hemofiltration, hemodialysis, or a combination of both methods. This therapy is a different process as compared to conventional renal replacement therapies as it is carried out continuously in an ICU setting.

In recent years, this procedure has gained significant attention due to the increasing prevalence of Acute Kidney Injury (AKI) and advancements in technology. Other factors attributable to the market growth include a rapidly growing number of ICU admissions across the world, rising incidence of sepsis-related acute kidney injury, and constant new product launches by key industry players.

• For instance, according to the U.S. Centers for Disease Control and Prevention (CDC) data published in August 2023, annually, 1 in 3 people dying in hospitals had sepsis during their hospitalization. Among the common complications in critically ill patients, sepsis-associated acute kidney injury (S-AKI) is prominent, contributing to the growing demand for this therapy. It is also linked with a high rate of morbidity and mortality.

The outbreak of COVID-19 had a positive impact on the market in 2020. This was primarily due to the high number of COVID-19 patients developing acute kidney injury, and thus, requiring ICU admissions. As this procedure is commonly used for patients admitted to the ICU, higher number of ICU admissions resulted in an increased demand for CRRT products and services.

However, the market witnessed a comparatively lower growth rate in 2021 due to the reduced usage of this therapy with the decreasing number of COVID-19 patients. The market witnessed a negative impact on the growth in 2022 on account of the decline in the demand for CRRT products due to the drop in the number of cases of COVID-19 associated AKI. The market is anticipated to witness steady growth during the forecast period of 2024-2032.

Continuous Renal Replacement Therapy Market Trends

Surging Preference for Continuous Venovenous Hemodiafiltration (CVVHDF) Modality in this Therapy 

In recent years, the market has witnessed several technological advancements, resulting in an increasing preference among healthcare professionals for Continuous Venovenous Hemodiafiltration (CVVHDF) as a treatment modality.

Owing to the several advantages offered by Continuous Venovenous Hemodiafiltration (CVVHDF), this modality is increasingly being preferred by in the management of critically ill patients with acute kidney injury. Some of the advantages of this modality include more hemodynamic stability than Intermittent Hemodialysis (IHD), continuous removal of uremic toxins and fluid, and others.

CRRT Market Growth Factors

Growing Number of ICU Admissions to Propel Market Growth

The constant increase in the number of patients admitted to intensive/critical care units across the globe is one of the key factors that has driven the continuous renal replacement therapy market growth. Acute kidney injury is one of the common complications occuring in patients admitted in ICUs and is recognized as a major public concern across the globe. The usage of this therapy consistently demonstrates a considerable impact on the management of critically ill patients. This therapy is provided in intensive care unit only for patients having acute kidney injury caused due to several other severe complications such as cancer, diabetes, cardiac surgery, and others. It can be given for 24 hours or a longer duration based on patients’ medical condition.

• For instance, as per the Society of Critical Care Medicine, each year, more than 5 million patients are admitted in intensive care units in the U.S. for various acute or life-threatening medical problems.


• Similarly, according to an article published in October 2020 by the National Center for Biotechnology Information (NCBI), in the U.K., approximately 13% to 18% of the total hospitalized patients experience acute kidney injury in the U.K.

Furthermore, the growing  geriatric population has led to a surge in ICU admissions across the world. The growing geriatric population is anticipated to increase the demand for the treatment and management of acute and chronic health conditions, especially, hypertension, cancer, heart disease, diabetes, and stroke which often require intensive care. Such factors are expected to contribute to the increase in the market size.

• For instance, as per the data published by the Population Reference Bureau (PRB) in January 2024, the number of American individuals aged 65 years and above is expected to reach 82 million by 2050, witnessing an increase of 47% as compared to 2022. This number was 58 million in 2022.


• Additionally, as per World Population Prospects of the United Nations, 2019, the number of individuals under age group 65 years and over in 2050 in Europe and North America is expected to reach 296.2 million.

Thus, the increasing geriatric population is anticipated to increase the number of ICU admissions which may require this therapy to manage their health conditions. All the above-mentioned factors are anticipated to propel the market expansion throughout the forecast period.

Rapid Advancements and Launches of New Technologies to Spur Market Growth 

Rapid technological advancements and introduction of new innovative products for this therapy has increased its adoption in managing critically ill patients. To meet the continuously evolving demand for CRRT products, the market players are focusing on developing products tailored to specific patient population, such as pediatric patients.

• For instance, in December 2020, Medtronic introduced Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine which is specially designed for pediatric and neonatal patients. This system is intended for use in cases involving fluid overloaded or acute kidney injury (AKI) patients requiring hemofiltration or hemodialysis therapy, and it can be suitable for patients weighing between 2.5-10 kilograms.

Furthermore, improvements in membrane technology and personalization of continuous renal replacement therapy delivery, along with other extracorporeal therapies are expected to offer additional advantages to patients. Moreover, the usage of data analytics in therapy delivery, automated prescription, and the development of quality metrics also contribute to enhancing the quality of care provided to patients. Such factors are estimated to boost the market size.

RESTRAINING FACTORS

Stringent Regulatory Guidelines for CRRT Therapy to Hinder Market Growth

Even though the application of continuous renal replacement therapy for ICU patients holds high potential in managing the burden of acute kidney injury, the presence of stringent regulatory guidelines for product manufacturing and approvals may impede the market growth.

Regulatory authorities across the globally such as the U.S. FDA have imposed strict regulatory requirements for the manufacturing of CRRT products to ensure the availability of high-quality systems in critical/intensive care units for this therapy. Owing to these stringent regulatory guidelines, several products that are already approved in other countries are yet to gain approvals in key countries such as the U.S.

• For instance, in August 2020, the U.S. FDA approved Baxter’s Regiocit, a replacement solution for CRRT for emergency use during COVID-19 pandemic. However, this product only has an emergency use authorization (EUA) in the U.S. but it is approved and currently in use in several countries across Asia and in Europe.

Hence, the presence of stringent regulations, leading to difficulties in access to these systems, is anticipated to slow down the market growth during the forecast period. In addition, higher cost associated with their installation and management compared to other renal replacement therapies is also set to hamper market growth.

Continuous Renal Replacement Therapy Market Segmentation Analysis

By Product Type Analysis

Consumables Segment Dominated the Market Owing to Strong Demand for These Products

Based on product type, the market is divided into systems and consumables. The consumables segment is further sub-segmented into dialysates, replacement solutions, filters, catheters, and others.

The consumables segment accounted for the highest market share in 2023 owing to several factors, such as relatively lower prices, repetitive consumption, as well as frequent purchases of these products by patients undergoing AKI treatment. In addition, the COVID-19 pandemic resulted in an increased demand for these products due to the increasing incidence of Acute Kidney Injury (AKI) among COVID-19 patients. Moreover, key players are also focusing on launches of new products as well as obtaining regulatory approvals to fulfill the growing market demands.

• For instance, in August 2020, Baxter received emergency use authorization (EUA) from the U.S. FDA for its Regiocit replacement solution to be used as a replacement solution in this therapy for patients requiring regional citrate anticoagulation during the COVID-19 pandemic.

On the other hand, the systems segment is anticipated to witness a considerable growth throughout the forecast period. The growth is attributed to higher demand for technologically advanced systems in developed countries compared to the developing countries. In recent years, leading players have focused on the introduction of advanced products to tap into untapped market opportunities.

• For instance, in May 2021, Baxter introduced PrisMax 2, the latest version of its continuous renal replacement and organ support therapy system. The company aimed to launch this product in more than 20 countries to strengthen its market dominance.

By Modality Analysis

Continuous Venovenous Hemodiafiltration (CVVHDF) Segment Dominated Due to Increasing Preference of this Modality

Based on modality, the market is segmented into Slow Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF).

The Continuous Venovenous Hemodiafiltration (CVVHDF) segment captured the highest global continuous renal replacement therapy market share in 2023. The dominance of this segment is majorly attributed to CVVHDF’s ability to completely remove and replace solutes and fluids from the patient’s blood. This therapy is an ideal combination of diffusion and convection to provide clearances over a broad range of solutes. As a result, CVVHDF is the preferred modality in several developed countries.

On the other hand, Continuous Venovenous Hemofiltration (CVVH) was the second-largest revenue generating segment in 2023. Increasing adoption of this modality in developing countries along with the rising number of patients with fluid overload are some of the factors that are supporting the segmental growth. Additionally, Slow Continuous Ultra Filtration (SCUF) and Continuous Venovenous Hemodialysis (CVVHD) are expected to witness reasonable growth throughout the forecast period. Slow Continuous Ultra Filtration (SCUF) is one of the less preferred modes of this procedure by the healthcare professionals prescribing this therapy. Continuous Venovenous Hemodialysis (CVVHD) is considered to be an effective method for the removal of small to medium sized molecules.

REGIONAL INSIGHTS

On the basis of region, the global market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America held a dominant position in the market and generated a revenue of USD 0.42 billion in 2023. Key factors driving the dominance of the region include high incidence of acute kidney (AKI) injury among ICU patients, stronger demand for therapy-related products compared to other regions, and presence of well-established healthcare infrastructure. Additionally, increasing support from regulatory bodies and the robust presence of product manufacturers in the region also supports the high market share of the region. For instance, in April 2022, Baxter International Inc. received the 510(k) clearance from U.S. Food and Drug Administration for its ST Set used in this therapy. The device can be used with PrisMax or Prismaflex control units.

On the other hand, Europe accounted for the second largest share in the global market. Increasing regulatory approvals in European Union and growing number of cases receiving renal replacement therapy are some of the factors that are driving the European market growth.

• For instance, according to a study published by Kidney Research UK in June 2023, the incidence of AKI in U.K. is expected to reach 637,000 by 2033 from an estimated 615,000 episodes in 2022.

The Asia Pacific region is expected to witness the fastest growth during the forecast period. In this region, countries such as Japan and China are expected to demonstrate considerable growth prospects. In Japan, the incidence of AKI accounts for approximately 40% of total ICU admissions and AKI contributes to around 26% of total in-hospital deaths in the country. This high incidence is expected to result in a high demand for renal replacement therapy in the region.

Furthermore, the Latin America and Middle East & Africa regions are expected to witness considerable growth over the forecast period. Factors contributing to this growth include the rising adoption of continuous renal replacement therapy in ICU patients in Latin America region, increasing incidence of acute kidney injury in hospitalized patients, and increasing partnerships between domestic and global players in these regions to offer advanced products.

• For instance, in June 2020, CytoSorbents Corporation launched the CytoSorb blood purification technology in Latin America. The product was distributed in various Latin American countries during COVID-19 to treat patients grappling with life-threatening COVID-19 and acute kidney injury (AKI). This was used in association with CRRT to improve mortality rates amongst the patients.

List of Key Companies in CRRT Market

Baxter to Lead due to Strong Product Offerings and Wider Distribution Network

The competitive scenario of this market reflects a consolidated market structure with leading players such as Baxter, Fresenius Medical Care AG & Co. KGaA (Germany), and B Braun SE accounting for a significant share in 2023. These key players are persistently focusing on expanding their product offerings and entering strategic partnerships with other companies and healthcare providers in order to expand their customer base.

• For instance, in March 2022, B. Braun announced the acquisition of Intermedt Medizin & Technik GmbH. The acquisition would enhance the company's comprehensive range of products and services for dialysis therapy.

Apart from these players, other prominent players, such as Medtronic, Asahi Kasei Medical Co., Ltd., Infomed SA, and others are also undertaking various strategic initiatives. These initiatives include the introduction of new innovative products and increased investment in R&D expenditure to strengthen their market presence.

• For instance, in August 2023, Quanta Dialysis Technologies – a U.K. based medical technology company received the U.S. FDA approval for the expanded use of its Quanta Dialysis System. This approval included two new CRRT modalities.

LIST OF KEY COMPANIES PROFILED:

• Baxter (U.S.)


• B Braun SE (Germany)


• Fresenius Medical Care AG & Co. KGaA (Germany)


• Asahi Kasei Medical Co., Ltd. (Asahi Kasei Corporation) (Japan)


• NIPRO (Japan)


• TORAY MEDICAL CO, LTD. (TORAY INDUSTRIES, INC.) (Japan)


• Nikkiso Co., Ltd. (Japan)


• Medtronic (Ireland)

KEY INDUSTRY DEVELOPMENTS

• December 2023 - Cheshire Medical Center, a member of Dartmouth Health, started offering Continuous Renal Replacement Therapy (CRRT) for ICU patients suffering from kidney failure.


• November 2023 - Horizon Health Network expanded its dialysis program to include Continuous Renal Replacement Therapy (CRRT) for patients staying at The Moncton Hospital (TMH).


• June 2023 – A professor from the University of Alabama at Birmingham received a grant of USD 3.8 million for the use of artificial intelligence (AI) in CRRT. The project name is Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement Therapy.


• January 2023: Peconic Bay Medical Center in Riverhead, New York started offering continuous renal replacement therapy for critically ill patients.


• January 2023: Baxter International Inc. announced a strategic roadmap to enhance its operational effectiveness. These changes include the plan to spin-off the company's Renal Care and Acute Therapies global business units into an independent company.


• August 2022: Fresenius Medical Care North America introduced the Speedswap system that can be used with NxStage System One with NxView to reduce downtime, lower treatment cost, and ease nursing load for this therapy in critical care settings.


• May 2020: Fresenius Medical Care AG & Co. KGaA received the Emergency Use Authorization (EUA) from U.S. Food and Drug Administration for multiBic dialysate solutions to use in continuous renal replacement therapy due to the acute care settings during the COVID-19 pandemic.

REPORT COVERAGE

The global market forecast provides an in-depth analysis of the industry. It focuses on key aspects such as leading companies, product type, and modality. Besides this, the report offers insights into market trends, new product launches, key industry developments, and technological advancements. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market in recent years. The report also provides the competitive landscape of the global market.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 7.9% from 2024-2032
Unit	Value (USD billion)
Segmentation	By  Product Type Systems Consumables Dialysates Replacement Solutions Filters Catheters Others
By Modality Slow Continuous Ultra Filtration (SCUF) Continuous Venovenous Hemofiltration (CVVH) Continuous Venovenous Hemodialysis (CVVHD) Continuous Venovenous Hemodiafiltration (CVVHDF)
By Region North America (By Product Type, By Modality, By Country) U.S. Canada Europe (By Product Type, By Modality, By Country/Sub-Region) U.K. Germany France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Product Type, By Modality, By Country/Sub-Region) Japan China India Australia Southeast Asia Rest of Asia Pacific Latin America (By Product Type, By Modality, By Country/Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Product Type, By Modality, By Country/Sub-Region) South Africa GCC Rest of Middle East & Africa